Cargo jettisons remaining assets and 90% of workforce as it looks for reverse merger
Just a few months after dumping its lead asset and cutting its workforce in half, Cargo Therapeutics is jettisoning even more of its load. The CAR-T firm is dropping its B-cell disease prospect CRG-023 and suspending development of its allogeneic platform, along with cutting about 90% of its workforce.
Just a few months after dumping its lead asset and cutting its workforce in half, Cargo Therapeutics is jettisoning even more of its load. The CAR-T firm is dropping its B-cell disease prospect CRG-023 and suspending development of its allogeneic platform, along with cutting about 90% of its workforce.
